BioXcel Therapeutics, Inc. — Director's Dealing 2019

May 29, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2019-05-23

Reporting Person: Mehta Vimal (Director, CEO, President and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-23	Stock Option (Right to Buy)	$10.04	A	187700	Acquired	2029-05-23	Common Stock (187700)	Direct

Footnotes

F1: The option will vest and become exercisable immediately as to 25% of the shares and the remaining 75% in equal monthly installments thereafter until the third anniversary of the grant date.